Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Reported November 13, 2025: Oramed Pharmaceuticals Q3 EPS $1.26 Beats $(0.08) Estimate, Sales $2.000M

Author: Benzinga Newsdesk | November 17, 2025 08:58am
Oramed Pharmaceuticals (NASDAQ:ORMP) reported quarterly earnings of $1.26 per share which beat the analyst consensus estimate of $(0.08) by 1675 percent. This is a 672.73 percent increase over losses of $(0.22) per share from the same period last year. The company reported $2.000 million in sales this quarter.

Posted In: ORMP


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist